Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned an average rating of “Moderate Buy” from the twenty-one ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $182.95.

A number of equities research analysts have commented on the stock. Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Barclays decreased their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald restated a “neutral” rating and set a $152.00 target price on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Finally, Citigroup decreased their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $128.42 on Friday. The firm’s 50 day moving average price is $128.97 and its 200-day moving average price is $132.40. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $12.14 billion, a PE ratio of 1,167.45 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. During the same quarter in the prior year, the business earned ($0.27) EPS. The business’s quarterly revenue was up 38.9% on a year-over-year basis. Equities research analysts expect that Sarepta Therapeutics will post 1.45 EPS for the current year.

Insiders Place Their Bets

In other news, Director Michael Andrew Chambers acquired 37,038 shares of the company’s stock in a transaction on Friday, August 16th. The stock was bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Michael Andrew Chambers acquired 37,038 shares of the company’s stock in a transaction on Friday, August 16th. The stock was bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Sarepta Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after purchasing an additional 243,180 shares during the last quarter. Capital International Investors lifted its position in shares of Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after purchasing an additional 76,032 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Sarepta Therapeutics by 6.3% during the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after purchasing an additional 37,940 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Sarepta Therapeutics by 26.3% during the first quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company’s stock worth $75,040,000 after purchasing an additional 120,535 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.